

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

TOUMAI® LAPAROSCOPIC SURGICAL ROBOT COMMERCIAL ORDERS EXCEEDING 200 UNITS WORLDWIDE

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company the updates on the latest business development of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, as of the date of this announcement, the Group’s core product, Toumai® Laparoscopic Surgical Robot (“**Toumai**”), has received over 200 commercial orders worldwide, covering nearly 50 countries and regions, and achieved commercial installations of approximately 130 units. The further milestone leap forward in the commercial orders and installation base of Toumai symbolizes the sustained and widespread recognition of its clinical value around the world, and is a systematic certification of the safety, stability and reliability of Toumai. Surgeons from diverse countries, healthcare systems and specialist backgrounds are integrating Toumai into their daily surgical practices and long-term discipline development through authentic and prudent clinical decision-making.

Among the nearly 50 covered countries and regions, 12 have ordered more than 5 units. Emerging markets such as India, Brazil and Argentina have shown strong growth, of which the cumulative number of orders in India has reached 14 units, and in Brazil over 10 units; the developed country markets have continued to make breakthroughs, with Spain, Australia and other countries becoming the fast growing points. The commercialization of Toumai has formed a new pattern of synergy and resonance in multiple regions around the world, penetrating through emerging markets in developing countries as well as mature healthcare systems in developed countries.

While continually accelerating its global expansion, Toumai has also been making breakthroughs in the depth of single-center clinical applications. According to internal statistics, dozens of medical institutions in various countries that have completed the commercial installation of Toumai have performed more than 100 surgeries per single-center, covering a wide range of departments including urology, general surgery, thoracic surgery, gynecology, pediatric surgery, and head and neck surgery.

As the world's first remote surgical robot system approved for commercial application, Toumai remote surgical robot has been approved for listing in nearly 10 countries, including China, India and Brazil. Its application has covered areas with nearly half of the world's population and has taken the lead in entering the stage of routine and large-scale clinical application. So far, Toumai has completed nearly 800 remote surgeries, covering more than 20 countries, and the implementation success rate continued to maintain 100%.

The Board wishes to remind the shareholders and potential investors of the Company that the above information is unaudited and is based on preliminary internal information of the Group, which may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such information.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 12 February 2026

As at the date of this announcement, the executive Directors are Dr. Chao He and Mr. Yu Liu, the non executive Directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive Directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.